Announcements
- Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
- Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
- Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
- Terns Pharmaceuticals Announces Leadership Changes
- Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024
- Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
- Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
- Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
- Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
- Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
More ▼
Key statistics
On Friday, Terns Pharmaceuticals Inc (430:BER) closed at 5.55, 79.32% above the 52 week low of 3.10 set on Nov 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.45 |
---|---|
High | 6.45 |
Low | 5.55 |
Bid | 5.45 |
Offer | 5.70 |
Previous close | 6.30 |
Average volume | 58.50 |
---|---|
Shares outstanding | 64.68m |
Free float | 63.53m |
P/E (TTM) | -- |
Market cap | 388.71m USD |
EPS (TTM) | -1.26 USD |
Data delayed at least 15 minutes, as of May 31 2024 19:08 BST.
More ▼